ideasIdea
In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma
Some new medicines reprogramme immune cells inside the body with an injection, skipping the factory entirely. Test whether that makes CAR-T affordable and available in ordinary hospitals.
In vivo CAR-T uses targeted lipid nanoparticles or engineered lentiviral vectors to deliver the CAR gene to T cells inside the patient (programmes from Interius, Umoja, Orna, Capstan and others entered the clinic in 2024-25). This idea is not about which antigen to hit but about manufacturing and delivery economics: a frozen vial produced in batches of thousands, administered in a community hospital with no apheresis, no bridging chemotherapy and possibly no lymphodepletion. A companion idea in this corpus covers solid-tumour antigens.
Hypothesis
An in vivo CD19 CAR-T product can be produced at a cost of goods below $10,000 per dose and delivered in non-academic centres with complete response rates in relapsed B-cell lymphoma within 15 percentage points of autologous CAR-T, and with a shorter time from decision to treatment.
Rationale
Batch manufacture of a nucleic acid-lipid product is the same industrial process that produced billions of mRNA vaccine doses; the marginal cost is orders of magnitude below a bespoke cell product, and the logistics collapse to a cold chain.
What would test it
Phase 2 in relapsed large B-cell lymphoma at community and academic sites, with pre-specified endpoints for cost of goods, time from enrolment to infusion, and response rate; compare with matched autologous CAR-T recipients.
Maturity
early clinical
Who has to act
industry
Cost to try
Large (over $50M)
Years to first evidence
4
Bottlenecks it attacks
- Manufacturing cost and time for living and radioactive medicines · Cell therapies take weeks to make for one patient and cost hundreds of thousands of dollars. Isotopes run short.
- Most of the world has almost no cancer care · Seven in ten cancer deaths happen in low- and middle-income countries, where radiotherapy, pathology, surgery and drugs are scarce.